RespireRx Pharmaceuticals Inc
Change company Symbol lookup
Select an option...
RSPI RespireRx Pharmaceuticals Inc
PMT PennyMac Mortgage Investment Trust
GS Goldman Sachs Group Inc
HLBZ Helbiz Inc
SRNE Sorrento Therapeutics Inc
OKTA Okta Inc
AAPL Apple Inc
CBTTF Cathedra Bitcoin Inc
IPVF InterPrivate III Financial Partners Inc
MFD Macquarie/First Trust Global Infrastructure/Utilities Dividend & Income
Go

Health Care : Pharmaceuticals | Small Cap Value
Company profile

RespireRx Pharmaceuticals Inc. is engaged in the discovery and development of medicines for the treatment of psychiatric and neurological disorders. The Company is developing treatment options that address obstructive sleep apnea (OSA), attention deficit hyperactivity disorder (ADHD) epilepsy, chronic pain, including inflammatory and neuropathic pain, and recovery from spinal cord injury (SCI), which are conditions that affect people. It is developing a pipeline of new and re-purposed drug products based on its patent portfolios for two drug platforms: pharmaceutical cannabinoids platform, is developing compounds that target the body’s endocannabinoid system, and in particular, the re-purposing of dronabinol, an endocannabinoid CB1 and CB2 receptor agonist, for the treatment of obstructive sleep apnea (OSA) and neuromodulators platform includes AMPAkines that are positive allosteric modulators (PAMs) of AMPA-type glutamate receptors and GABAkines that are PAMs of GABAA receptors.

Closing Price
$0.0064
Day's Change
0.00 (0.00%)
Bid
--
Ask
--
B/A Size
--
Day's High
0.0075
Day's Low
0.0064
Volume
(Below Average)
Volume:
190,200

10-day average volume:
692,601
190,200

Earnings information for RSPI is not available.

Market data accompanied by is delayed by at least 15 minutes for NASDAQ, NYSE MKT, NYSE, and options. Duration of the delay for other exchanges varies.
Market data and information provided by Morningstar.

Information provided by Copyright © 2022. All rights reserved.

Reuters content is the intellectual property of Reuters. Any copying, republication or redistribution of Reuters content, including by caching, framing or similar means, is expressly prohibited without the prior written consent of Reuters. Reuters is not liable for any errors or delays in content, or for any actions taken in reliance on any content. Reuters, Reuters Logo and the Sphere Logo are trademarks and registered trademarks of the Reuters Group of companies around the world.

Data is provided for information purposes only and is not intended for trading purposes. Reuters shall not be liable for any errors or delay in the content, or for any action taken in reliance on any content. The RIC or Reuters Instrument Code set has been developed and maintained by Reuters and is the intellectual property of Reuters.